Physician profile
Marykate Morcerf
NPI 1639745581
$2,834.42
in general payments reported to CMS, 2019-2025
42 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.15 · 2022: $1,228 · 2023: $815 · 2024: $18.49 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $270.39 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $265.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.03 | 2023-2025 | Reblozyl, Opdualag, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $189.56 | 2022-2023 | Ninlaro |
| Janssen Biotech, INC. | $187.23 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $137.97 | 2022-2025 | |
| Genzyme Corporation | $103.76 | 2021-2022 | |
| Seagen INC. | $99.00 | 2022-2023 | Tivdak |
| Morphosys, US INC. | $92.56 | 2022-2023 | Monjuvi |
| Incyte Corporation | $87.31 | 2022-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $80.11 | 2022-2025 | Keytruda |
| Pharmaessentia USA Corporation | $79.62 | 2022-2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $75.01 | 2022-2025 | Imfinzi |
| Abbvie INC. | $70.19 | 2023-2025 | |
| Celgene Corporation | $64.30 | 2022-2025 | Reblozyl |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.82 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Sobi, INC | $61.69 | 2022-2025 | |
| Glaxosmithkline, LLC. | $59.16 | 2023-2025 | Ojjaara, Jemperli |
| Deciphera Pharmaceuticals INC. | $50.53 | 2023-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $48.36 | 2022 | |
| Genentech USA, INC. | $48.03 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Tersera Therapeutics LLC | $37.71 | 2022-2025 | Xermelo |
| Boston Scientific Corporation | $36.32 | 2022 | |
| Kyowa Kirin, INC. | $28.90 | 2025 | |
| Spectrum Pharmaceuticals INC. | $27.77 | 2023 | Rolvedon |
| Eisai INC. | $26.64 | 2025 | |
| Heron Therapeutics, INC. | $26.15 | 2022 | |
| Lilly USA, LLC | $26.11 | 2022 | |
| G1 Therapeutics, INC. | $24.76 | 2023 | Cosela |
| Array Biopharma INC | $24.73 | 2023 | Xalkori, Lorbrena, Braftovi |
| Global Blood Therapeutics, INC. | $24.12 | 2022 | |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Novocure INC. | $22.57 | 2023 | Optune |
| Nuvation Bio INC. | $22.00 | 2025 | Ibtrozi |
| Rigel Pharmaceuticals, INC. | $21.32 | 2022 | |
| Astellas Pharma US INC | $21.20 | 2025 | Xospata |
| Blueprint Medicines Corporation | $20.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.28 | 2023 | Ultomiris |
| Karyopharm Therapeutics INC. | $18.87 | 2022 | |
| Lundbeck LLC | $18.31 | 2022 | |
| Aimmune Therapeutics, INC. | $15.08 | 2025 | Zenpep |
| Recordati_rare_diseases_inc. | $13.74 | 2023 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marykate Morcerf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.